Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.740
0.00 (0.00%)
At close: Jul 17, 2026, 4:00 PM EDT
1.760
+0.020 (1.15%)
After-hours: Jul 17, 2026, 7:44 PM EDT
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or -53.33% compared to the previous year.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$5,846,216
Market Cap
74.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Alps Group | 93 |
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| PMV Pharmaceuticals | 54 |
| Enlivex | 34 |
| Gain Therapeutics | 21 |
| LeonaBio | 19 |
ANVS News
- 10 days ago - Annovis Bio initiated with a Buy at Roth Capital - TheFly
- 10 days ago - Annovis Bio announces full enrollment for buntanetap trial - TheFly
- 11 days ago - Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - GlobeNewsWire
- 16 days ago - Annovis Bio promotes Cheng Fang to chief scientific officer - TheFly
- 16 days ago - Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - GlobeNewsWire
- 7 weeks ago - Annovis Bio regains NYSE listing compliance - TheFly
- 7 weeks ago - Annovis Bio Regains NYSE Listing Compliance - GlobeNewsWire
- 2 months ago - Annovis Bio 7.9M share Spot Secondary priced at $1.90 - TheFly